Gene polymorphisms in association with emerging cardiovascular risk markers in adult women

Amy Z Fan1*, Ajay Yesupriya1, Man-huei Chang1, Meaghan House2, Jing Fang1, Renée Ned1, Donald Hayes1, Nicole F Dowling1, Ali H Mokdad3

Abstract

Background: Evidence on the associations of emerging cardiovascular disease risk factors/markers with genes may help identify intermediate pathways of disease susceptibility in the general population. This population-based study is aimed to determine the presence of associations between a wide array of genetic variants and emerging cardiovascular risk markers among adult US women.

Methods: The current analysis was performed among the National Health and Nutrition Examination Survey (NHANES) III phase 2 samples of adult women aged 17 years and older (sample size n = 3409). Fourteen candidate genes within ADRB2, ADRB3, CAT, CRP, F2, F5, FGB, ITGB3, MTHFR, NOS3, PPARG, TLR4, and TNF were examined for associations with emerging cardiovascular risk markers such as serum C-reactive protein, homocysteine, uric acid, and plasma fibrinogen. Linear regression models were performed using SAS-callable SUDAAN 9.0. The covariates included age, race/ethnicity, education, menopausal status, female hormone use, aspirin use, and lifestyle factors.

Results: In covariate-adjusted models, serum C-reactive protein concentrations were significantly (P value controlling for false-discovery rate ≤ 0.05) associated with polymorphisms in CRP (rs3093058, rs1205), MTHFR (rs1801131), and ADRB3 (rs4994). Serum homocysteine levels were significantly associated with MTHFR (rs1801133).

Conclusion: The significant associations between certain gene variants with concentration variations in serum C-reactive protein and homocysteine among adult women need to be confirmed in further genetic association studies.

Background

Coronary heart disease and stroke remain the leading causes of death and disability for men and women in the United States [1,2]. Atherosclerotic cardiovascular disease, which affects the heart, brain, and peripheral circulation, is responsible for the majority of the cases [3]. Traditional risk factors cannot fully account for the variation in the prevalence of heart disease in the general population. Some biomarkers, including C-reactive protein, fibrinogen, uric acid, and homocysteine, are among those which have been proposed as potential modifiable risk factors/markers in the last two decades. Inflammation plays a key role in the initiation, progression, and outcome of atherosclerosis [4,5]. In prospective studies, markers of inflammation such as C-reactive protein (CRP) and fibrinogen have been found to be predictive of atherosclerosis and an increased risk of CVD events [4-16]. Elevated levels of plasma homocysteine and serum uric acid have been associated with increased risk of cardio- or cerebrovascular disease [17-21]. In addition, these emerging cardiovascular risk biomarkers influence each other and are correlated with conventional risk factors/markers such as high blood pressure or hyperlipidemia [22-24].
The concentrations of all four emerging biomarkers (CRP, fibrinogen, uric acid, homocysteine) are caused by complex interactions between environmental risk factors and predisposing genes. The candidate genes in this study, i.e., ADRB2, ADRB3, CAT, CRP, F2, F5, FGB, ITGB3, MTHFR, NOS3, PON1, PPARG, TLR4, and TNF, have been suggested to confer excess risk of cardiovascular disease, although the results are inconsistent from different association studies [25]. These candidate genes were selected from a set of variants that were previously genotyped in the NHANES III genetic data [26] and were identified from systematic literature reviews of previously published candidate gene association studies and meta-analyses [27-33].

The evidence on the associations of four novel risk factors/markers with these genes may help identify intermediate pathways of CVD susceptibility in the general population. For example, because genetic traits confer a risk of inflammation, common gene polymorphisms (> 1% frequency in the general population) may explain an individual’s likelihood of developing inflammation or why some have a greater inflammatory response than others [34-36]. The National Health and Nutrition Examination Survey (NHANES) III DNA bank offers a unique sample to carry out this analysis as it has a large sample size and a diversity of ages, races and ethnicities that is representative of the US population. We examined the presence and magnitude of associations between candidate genetic variants (n = 27) within ADRB2, ADRB3, CAT, CRP, F2, F5, FGB, ITGB3, MTHFR, NOS3, PON1, PPARG, TLR4, and TNF [26,37] and four cardiovascular risk markers (CRP, fibrinogen, homocysteine, and uric acid) among adult women.

Methods

Study Sample

Participants took part in the second phase (1991-1994) of the Third National Health and Nutrition Examination Survey (NHANES III). The NHANES are complex, multistage cross-sectional sample surveys conducted by the National Center for Health Statistics (NCHS) of the Centers for Disease Control and Prevention (CDC). NHANES III included a stratified multistage probability design to provide national estimates of common diseases and their respective risk factors for the civilian noninstitutionalized population in the United States ages two months or older, from 1988 through 1994. Data collection for NHANES occurs at three levels: a brief household screener interview, an in-depth household survey interview, and an extensive medical examination [38]. Population weights are calculated for each individual to make the data representative of the US population. In the second phase of NHANES III, white blood cells were frozen and cell lines were immortalized with the Epstein-Barr virus, creating a DNA bank. The current analysis was performed among adult women aged 17 years and older (n = 3409). The study was approved by the NCHS Ethics Review Board. NHANES III DNA bank, selection of candidate genes and variants, genotyping methods, and quality controls are detailed elsewhere [26].

Genotyping Methods

Most genotypes were assayed either by TaqMan (5’ nuclease assay; Applied Biosystems, Foster City, CA) or by the MGB Eclipse Assay (3’ hybridization triggered fluorescence reaction; Nanogen, Bothwell, WA). ADRB2 and F2 were genotyped using pyrosequencing. Water controls and DNA samples with known genotypes, purchased from Coriell Cell Repository (Camden, NJ) were included on each well plate [26].

Biochemical Analysis

The laboratory procedures for the assessment of serum C reactive protein, serum uric acid, serum homocysteine and plasma fibrinogen are available from the NCHS website [39].

Covariates

Potential confounders of the gene-outcome relationship were selected a priori. Demographic characteristics include age (17-40 yrs, 41-59 yrs, 60 + yrs), race-ethnicity (non-Hispanic white, non-Hispanic black, Mexican American), and educational attainment (< 12 yrs, 12 yrs, college and above). Lifestyle factors include smoking status (current, former, never), drinking status (lifetime abstainer, former drinker, current drinker), total dietary fiber intake (≥ or < 7 gm/1000 kcal), total energy intake (≥ or < 1600 kcal per day), and physical activity (none, low, high). Other covariates include BMI (< 25 kg/m², 25-29.9 kg/m², ≥ 30 kg/m²), menopausal status (yes/no), female hormone use (yes/no), and aspirin use (yes/no). Details on descriptions of covariates are available elsewhere [32].

Statistical Analysis

Weighted allele frequencies of genetic variants in the US population by race/ethnicity using the NHANES III phase 2 DNA bank have been presented elsewhere [26]. Deviations from Hardy-Weinberg proportions were tested in a standard unweighted analysis using Chi-square goodness-of-fit approach. Point estimates and 95% confidence intervals for the distribution of the demographic, lifestyle and biomarker variables were calculated. The Taylor series linearization approach was used to estimate the variance for standard errors.

Adjusted means of the outcome variables (inflammation markers) by gene variants were obtained from multiple linear regression models. Candidate covariates/potential confounders included age, race/ethnicity, education, menopausal status, female hormone use, smoking
status, drinking status, dietary fiber intake, total energy intake, physical activity, body mass index, and aspirin use. However, only significant covariates “in the crude models” were retained in fully-adjusted models for a specific marker predicted by certain genetic variants. For CRP, total energy intake was excluded; for fibrinogen, dietary fiber intake was excluded; for homocysteine, drinking status was excluded; and for uric acid, drinking status and aspirin use were excluded. Minimally adjusted models were also presented with adjustment of only race/ethnicity. We presented adjusted means by genotype [40] and made groupwise comparisons. A P value ≤ 0.05 of the Satterthwaite-adjusted F-statistic in fully adjusted models was considered as statistically significant. False Discovery Rate (FDR)-adjusted P values (adjusted for a maximum of 27 tests) are presented along with unadjusted P values from Wald Chi-square tests. All outcome variables were right-skewed and were thus log-transformed before analysis. The analyses were performed in SAS-callable SUDAAN 9.01 (Research Triangle Institute, NC, 2007) to account for the complex sampling design, non-response, and sample weights for Genetic Component of NHANES III.

**Results**

Characteristics of the study population based on the 3,409 participants are described in Table 1. The weighted frequency distribution was 81.3% non-Hispanic white, 13.2% non-Hispanic black, and 5.6% Mexican American. Current smokers accounted for 25.7% of the study population, while 43.3% were current drinkers. Approximately 41% of women have undergone menopause; and about 16% were currently using any form of female hormone. The correlation matrix for the four logarithm-transformed biomarkers is shown in Additional File 1: Table S1. The Pearson correlation coefficients ranged from 0.04 to 0.39.

In fully-adjusted models, serum C-reactive protein concentrations were significantly associated with polymorphisms in **CRP** (rs3093058, rs1205), **MTHFR** (rs1801131), **ADRB3** (rs49994) (Table 2). Plasma fibrinogen levels were significantly associated with **TNF** (rs1800750), though not after adjustment for multiple testing (Table 3). Serum uric acid levels were significantly associated with **CRP** (rs1417938) and **TNF** (rs361525), though also not after correction for multiple testing (Table 4). Serum homocysteine levels were significantly associated with **F2** (rs1799963), **MTHFR** (rs1801131, rs1801133, rs2066470) and **ADRB2** (rs1042713) (Table 5). However, only rs1801133 remained significant with an FDR-adjusted P value of 0.005. Compared with minimally adjusted models, most associations became more significant in fully adjusted models. The following data for the concentrations of the

---

### Table 1 Characteristics of study population of US women, Third National Health and Nutrition Examination Survey, Phase 2 (1991-1994)

| Category                        | Percent (Standard Error) |
|---------------------------------|--------------------------|
| **Age**                         | N = 3,409                |
| 17-40                           | 45.6 (1.8)               |
| 41-59                           | 30.2 (1.6)               |
| 60+                             | 24.2 (2.2)               |
| **Race/Ethnicity**              |                          |
| Non-Hispanic white              | 81.3 (1.8)               |
| Non-Hispanic black              | 13.2 (1.7)               |
| Mexican American                | 5.6 (0.8)                |
| **Educational attainment**      |                          |
| < 12 yrs                        | 22.1 (1.6)               |
| 12 yrs                          | 37.5 (1.4)               |
| College or above                | 40.4 (2.4)               |
| **BMI (kg/m²)**                 |                          |
| < 25                            | 48.1 (1.9)               |
| 25-299                          | 25.4 (0.8)               |
| ≥ 30                            | 26.5 (1.4)               |
| **Smoking status**              |                          |
| Current smoker                  | 25.7 (1.5)               |
| Former smoker                   | 18.7 (1.4)               |
| Never smoker                    | 55.6 (1.8)               |
| **Drinking status**             |                          |
| Lifetime abstainer              | 17.9 (1.7)               |
| Former drinker                  | 38.8 (1.3)               |
| Current drinker                 | 43.3 (2.2)               |
| **Total dietary fiber intake**  |                          |
| ≥ 7 gm/1000 kcal                | 59.8 (1.9)               |
| < 7 gm/1000 kcal                | 40.2 (1.9)               |
| **Total energy intake**         |                          |
| ≥ 1600 kcal                     | 56.4 (1.4)               |
| < 1600 kcal                     | 43.6 (1.4)               |
| **Physical activity**           |                          |
| None                            | 22.7 (2.1)               |
| Low                             | 35.3 (1.1)               |
| High                            | 42.0 (1.9)               |
| **Menopausal status**           |                          |
| Yes                             | 40.7 (2.2)               |
| No                              | 59.3 (2.2)               |
| **Aspirin use**                 |                          |
| None                            | 68.0 (1.2)               |
| < 1 day/month                   | 30.1 (1.1)               |
| ≥ 1 day/month                   | 18.0 (0.4)               |
| **Female hormone use**          |                          |
| Yes                             | 16.0 (1.4)               |
| No                              | 84.0 (1.4)               |
| **Serum C-reactive protein (mg/dL)**a | 0.33 (0.31,0.35) |
| **Plasma fibrinogen (g/L)**a    | 3.00 (2.95, 3.06)        |
| **Serum homocysteine (umol/L)**a| 8.17 (8.01, 8.33)        |
| **Serum uric acid (umol/L)**a   | 270 (265, 276)           |

---

a Data are geometric mean (95% confidence interval).
four biomarkers in relation to the 27 candidate SNPs from minimally-adjusted and fully adjusted models are shown in additional file 1 available online (URL): the adjusted least-square means (LSMEANS) and standard errors (SE), exponentiated adjusted LSMEANS (CI), and P values for Satterthwaite adjusted F-statistic.

Discussion

Cardiovascular diseases are multi-factorial as their pathogenesis is determined by genetic and environmental factors, as well as gene-gene and gene-environment interactions. This population-based genetic association study provides evidence that some intermediate CVD risk markers may be influenced by common genetic variants.

Numerous candidate gene studies have examined the role of inflammatory gene polymorphisms and the risk of CVD [41-45]. However, the findings remain inconsistent and the magnitude of associations remains modest [46]. C-Reactive protein is a systemic marker of inflammation and plays an important role in the pathogenesis of atherogenesis and its thrombotic complications. Plasma C-Reactive protein concentrations have been associated with CRP polymorphisms [42,43]. Although C-Reactive protein concentrations are a strong independent predictor of future vascular events, there has been no direct evidence that CRP variants contribute to cardiovascular disease phenotypes such as carotid intima-media thickness or arterial thrombosis [47-49].

Fibrinogen plays a key role in the final step of the coagulation cascade, i.e., the formation of fibrin; and it is a major determinant of plasma viscosity and erythrocyte aggregation. There is a large variation on estimates of the genetic heritability of plasma fibrinogen [44,45]. The researchers who estimated low heritability argued that environment, rather than genetic influences, has a greater effect on the level of plasma fibrinogen. It is also under debate whether plasma fibrinogen is a primary risk factor/mediator for coronary heart disease, or whether it is a marker for disease [50]. A large cohort study showed that fibrinogen may partly mediate the effects of other risk factors on carotid atherosclerosis, though it may not play a causal role [51]. The evidence from molecular biology seems to support the view that fibrinogen is a marker, rather than a mediator, of vascular disease [52]. Whether the association of plasma fibrinogen with the gene polymorphisms found in this report could be replicated in other genetic association studies remains unknown.

The findings that serum uric acid levels were associated with CRP and TNF polymorphisms need to be confirmed by other studies especially because the association was no longer significant after FDR adjustment. The underlying mechanisms need to be examined. In the literature, uric acid levels have been shown to be correlated with plasma levels of circulating TNF-alpha [53] and increased CRP expression [24]. Other genetic variants have been found to explain the variance in serum uric acid concentrations [54-56].

Plasma homocysteine is a thiol compound derived from methionine that is involved in two main metabolic pathways: the cycle of activated methyl groups, which requires folate and vitamin B12 as cofactors; and the transsulfuration pathway to cystathionine and cysteine, which requires vitamin B6 as a cofactor. Elevations in

| Table 2 Sample size and adjusted geometric means (95% confidence intervals) of serum C-reactive protein (mg/dL)* |
|---------------------------------------------------------------|
| Genotype          | Minimally adjusted model LSmean (95% CI) | \( \bar{P}_{\text{unadjusted}} \) | \( \bar{P}_{\text{FDR-adjusted}} \) | Fully adjusted model LSmean (95% CI) | \( \bar{P}_{\text{unadjusted}} \) | \( \bar{P}_{\text{FDR-adjusted}} \) |
|-------------------|------------------------------------------|----------------|----------------|-------------------------------------|----------------|----------------|
| rs3093058 (CRP)   |                                          | 0.0013         | 0.018          | 0.0012                              | 0.023          |
| TT                | 0.45 (0.29,0.71)                         |                |                | 0.44 (0.29,0.66)                     |                |                |
| TA                | 0.42 (0.37,0.49)                         |                |                | 0.41 (0.36,0.46)                     |                |                |
| AA                | 0.32 (0.30,0.34)                         |                |                | 0.32 (0.31,0.33)                     |                |                |
| rs1205(CRP)       |                                          | 0.0012         | 0.018          | 0.0059                              | 0.038          |
| AA                | 0.28 (0.26,0.31)                         |                |                | 0.29 (0.27,0.31)                     |                |                |
| AG                | 0.32 (0.30,0.34)                         |                |                | 0.32 (0.31,0.34)                     |                |                |
| GG                | 0.34 (0.32,0.37)                         |                |                | 0.34 (0.32,0.35)                     |                |                |
| rs1801131 (MTHFR) |                                          | 0.35           | 0.71           | 0.0024                              | 0.023          |
| TT                | 0.33 (0.29,0.36)                         |                |                | 0.30 (0.28,0.32)                     |                |                |
| TC                | 0.32 (0.30,0.34)                         |                |                | 0.32 (0.30,0.33)                     |                |                |
| CC                | 0.33 (0.31,0.35)                         |                |                | 0.33 (0.32,0.35)                     |                |                |
| rs4994 (ADRB3)    |                                          | 0.022          | 0.19           | 0.0026                              | 0.023          |
| CC                | 0.29 (0.20,0.42)                         |                |                | 0.29 (0.23,0.38)                     |                |                |
| CT                | 0.29 (0.27,0.31)                         |                |                | 0.29 (0.28,0.31)                     |                |                |
| TT                | 0.33 (0.31,0.35)                         |                |                | 0.33 (0.31,0.34)                     |                |                |

Note. *Only associations with unadjusted \( P \) (i.e., not adjusted for FDR) \( \leq 0.05 \) in fully adjusted models are presented. FDR = false discovery rate.
### Table 3 Adjusted geometric means (95% confidence intervals) of plasma fibrinogen (g/L)*

| Genotype         | Minimally adjusted model LSmean (95% CI) | Unadjusted   | PFDR-adjusted | Fully adjusted model LSmean (95% CI) | Unadjusted | PFDR-adjusted |
|------------------|------------------------------------------|--------------|---------------|--------------------------------------|------------|---------------|
| rs1800750 (TNF) |                                          | 0.13/0.86    |               | 2.8 (2.3,3.5)                        | 0.13/0.35  |               |
| AA               | 3.2 (2.5,4.1)                            |              |               | 2.8 (2.3,3.5)                        | 0.13/0.35  |               |
| AG               | 3.4 (2.9,3.9)                            |              |               | 3.5 (3.1,3.9)                        | 0.13/0.35  |               |
| GG               | 3.0 (2.9,3.1)                            |              |               | 3.0 (2.9,3.1)                        | 0.13/0.35  |               |

Note. *Only associations with unadjusted P (i.e., not adjusted for FDR) ≤ 0.05 in fully adjusted models are presented. FDR = false discovery rate.

### Table 4 Adjusted geometric means (95% confidence intervals) of serum uric acid (umol/L)*

| Genotype         | Minimally adjusted model LSmean (95% CI) | Unadjusted   | PFDR-adjusted | Fully adjusted model LSmean (95% CI) | Unadjusted | PFDR-adjusted |
|------------------|------------------------------------------|--------------|---------------|--------------------------------------|------------|---------------|
| rs361525 (TNF)  |                                          | 0.05/0.76    |               | 0.04/0.55                            |            |               |
| AA               | 225 (185-275)                            |              |               | 233 (195-279)                        |            |               |
| AG               | 258 (248-268)                            |              |               | 257 (246-268)                        |            |               |
| GG               | 272 (267-278)                            |              |               | 272 (268-276)                        |            |               |
| rs1417938 (CRP) |                                          | 0.16/0.76    |               | 0.03/0.55                            |            |               |
| TT               | 261 (248-273)                            |              |               | 259 (250-270)                        |            |               |
| TA               | 270 (265-274)                            |              |               | 268 (263-273)                        |            |               |
| AA               | 273 (267-278)                            |              |               | 274 (268-279)                        |            |               |

Note. *Only associations with unadjusted P (i.e., not adjusted for FDR) ≤ 0.05 in fully adjusted models are presented. FDR = false discovery rate.

### Table 5 Adjusted geometric means (95% confidence intervals) of serum homocysteine (umol/L)*

| Genotype         | Minimally adjusted model LSmean (95% CI) | Unadjusted   | PFDR-adjusted | Fully adjusted model LSmean (95% CI) | Unadjusted | PFDR-adjusted |
|------------------|------------------------------------------|--------------|---------------|--------------------------------------|------------|---------------|
| rs1801133 (MTHFR)|                                          | 0.0002/0.0054|               | 0.0002/0.0052                        |            |               |
| TT               | 9.9 (8.9-11.1)                           |              |               | 9.8 (8.9-10.8)                       |            |               |
| TC               | 8.2 (8.0-8.5)                            |              |               | 8.2 (7.9-8.5)                        |            |               |
| CC               | 7.7 (7.5-8.0)                            |              |               | 7.7 (7.6-7.9)                        |            |               |
| rs2066470 (MTHFR)|                                          | 0.05/0.46    |               | 0.02/0.28                            |            |               |
| TT               | 8.2 (7.4-9.1)                            |              |               | 8.1 (7.1-9.3)                        |            |               |
| TC               | 7.8 (7.5-8.1)                            |              |               | 7.7 (7.5-8.0)                        |            |               |
| CC               | 8.2 (8.0-8.4)                            |              |               | 8.2 (8.0-8.4)                        |            |               |
| rs1801131 (MTHFR)|                                          | 0.02/0.28    |               | 0.05/0.28                            |            |               |
| CC               | 7.9 (7.4-8.4)                            |              |               | 8.0 (7.3-8.8)                        |            |               |
| CA               | 7.8 (7.6-8.1)                            |              |               | 7.8 (7.5-8.1)                        |            |               |
| AA               | 8.5 (8.1-8.8)                            |              |               | 8.4 (8.1-8.7)                        |            |               |
| rs1799963 (F2)  |                                          | 0.16/0.85    |               | 0.039/0.28                           |            |               |
| AA               | .a                                        |              |               | -                                    |            |               |
| AG               | 7.7 (7.1-8.4)                            |              |               | 7.5 (6.9-8.2)                        |            |               |
| GG               | 8.2 (8.0-8.4)                            |              |               | 8.2 (7.9-8.3)                        |            |               |
| rs1042713 (ADRB2)|                                          | 0.17/0.85    |               | 0.04/0.28                            |            |               |
| AA               | 8.1 (7.7-8.6)                            |              |               | 8.1 (7.7-8.5)                        |            |               |
| AG               | 8.4 (8.1-8.7)                            |              |               | 8.4 (8.1-8.7)                        |            |               |
| GG               | 7.9 (7.6-8.2)                            |              |               | 7.8 (7.5-8.2)                        |            |               |

Note. *Only associations with unadjusted P (i.e., not adjusted for FDR) ≤ 0.05 in fully adjusted models are presented. FDR = false discovery rate. * The frequency is zero for this genotype.
plasma homocysteine may be caused by genetic defects in enzymes involved in its metabolism or by deficiencies in cofactor levels [57]. Although the genetic influence of MTHFR polymorphisms on homocysteine levels is well-known, it is under debate whether the MTHFR polymorphism per se might be an independent contributor to cardiovascular risk [58].

There are some limitations in this study. First, the NHANES DNA bank was set up mainly to assess the allele frequency of these genes in a population-based sample, but it may not necessarily be one of the strong study designs to do genetic association studies. Second, our candidate genes were not selected based solely on explicit molecular/cellular biological pathways. For example, our study shows significant associations between ADRB3 and MTHFR genes to be associated with concentrations of serum C-reactive proteins although ADRB3 was mainly proposed to be a candidate gene for blood pressure and MTHFR was for serum homocysteine. The results are not surprising because of complex pathogenetic connections between immunoinflammatory reactions, elevated homocysteine levels, and high blood pressure [59,60]. Third, the four biomarkers investigated in the study are largely influenced by environmental factors which may not be adequately captured by current study.

We did not investigate whether genetic and environmental factors modify each other in these associations. For example, hormone replacement therapy (especially estrogen) might be associated with increased inflammatory activity [61]. How genetic factors interact with inflammation-modulating effects of estrogen in causing adverse effects on atherogenesis or determining unfavorable clinical outcome is worthy of further investigation. Further studies are also needed to validate findings from recent genome-wide association studies that have revealed potential new SNPs [49,62,63].

Conclusion
Our study provides some evidence that genetic factors contribute to the pathogenesis of inflammation and other CVD risk markers among adult women. Such knowledge may lead to improved prevention and treatment efforts. Identifying the variants that may modify the levels of these risk markers may allow for improved targeting and treatment of individuals or populations at an increased risk for future CVD events.

Additional file 1: Supplemental Tables. Table S1. Exponentiated adjusted least-square means of concentrations of the four biomarkers (95% CIs) in relation to the 27 candidate SNPs from fully-adjusted linear regression models. The adjusted least-square means (LSMEANS) and standard errors (SE), exponentiated adjusted LSMEANS (CI), and P values for Satterthwaite adjusted F-statistic are shown. Table S2. Exponentiated adjusted least-square means of concentrations of the four biomarkers (95% CIs) in relation to the 27 candidate SNPs from fully-adjusted models, the adjusted least-square means (LSMEANS) and standard errors (SE), exponentiated adjusted LSMEANS (CI), and P values for Satterthwaite adjusted F-statistic are shown.

Acknowledgements
The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

This project was completed in partnership with the CDC/NCI NHANES III Genomics Working Group.

Author details
1 National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA. 2 School of Public Health, Emory University, 1518 Clifton Road NE, Atlanta, GA 30329, USA. 3 Institute for Health Metrics and Evaluation, University of Washington, 2301 5th Avenue Suite600, Seattle, WA 98121, USA.

Authors’ contributions
AZF conceived of the study, and participated in its design and drafted the manuscript, AV performed the statistical analysis, MH helped drafting the manuscript, WC participated in the design of the study and guided in statistical methodology, JJF participated in the design of the study, RN participated study design and interpretation of data, DH participated study design and interpretation of the data. NFD and AHM provided important comments to enrich the discussion. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 5 June 2009
Accepted: 15 January 2010
Published: 15 January 2010

References
1. Rosamond W, Flegal K, Furie K, Go A, Greenland K, Haase N, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O’Donnell CJ, Roger V, Rumsfeld J, Sotie P, Steinerberger J, Thom T, Wassertsch-Nikolowski, S, Hong Y: Heart disease and stroke statistics–2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007, 115(5):e69–171.
2. National Center for Health Statistics: Health, United States, 2008. With Special Features of the Health of Young Adults. Hyattsville, MD: Centers for Disease Control and Prevention 2008 http://www.cdc.gov/nchs/data/hus/hus08.pdf.
3. Hackam DG, Anand SS: Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA 2003, 290(7):932-940.
4. Gillum RF, Makuc DM: Serum albumin, coronary heart disease, and death. Am Heart J 1992, 123(2):507-513.
5. Harris TB, Ferrucci L, Tracy RP, Crotti MC, Wacholder S, Ettinger WH Jr, Heimovitz H, Cohen HJ, Wallace R: Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999, 106(5):506-512.
6. Ridker PM, Buring JE, Shih J, Matsis M, Hennekens CH: Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy men. Circulation 1998, 98(8):731-733.
7. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336(14):973-979.
8. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998, 97(4):425-428.
9. Ridker PM, Hennekens CH, Burin JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342(12):836-843.

10. Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ: Interrelation of hyperhomocysteinemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 1997, 95(7):1777-1782.

11. Koenig W, Sund M, Frohlich M, Fischer HG, Loewel H, Doring A, Hutchinson WL, Pelps MB: C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999, 99(2):237-242.

12. Tunstall-Pedoe H, Woodward M, Tavendale R, A’Brook R, McCluskey MK: Comparison of the prediction by 27 different factors of coronary heart disease and death in men and women of the Scottish Heart Health Study: cohort study. BMJ 1997, 315(710):722-729.

13. Koller LH, Tracy RP, Shaten J, Meilahn EH: Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996, 144(6):537-547.

14. Rosenson RS, Koenig W: Utility of inflammatory markers in the management of coronary artery disease. Am J Cardiol 2003, 92(1A):10-18.

15. Deneen J, Wheeler JW, Hirschfeld GM, Eda S, Eiriksdottir G, Runyan B, Lowe GQ, Pelps MB, Gudnason V: C-Reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004, 350(14):1387-1397.

16. Willerson JT, Ridker PM: Inflammation as a cardiovascular risk factor. Circulation 2004, 109(21 Suppl 1):I2-10.

17. Gagliardi AC, Miname MH, Santos RD: Uric acid: a marker of increased cardiovascular risk. Arterioscler Thromb Vasc Biol 2009, 29(1):11-17.

18. Moat SJ: Plasma total homocysteine: stimulator or indicator of cardiovascular disease?. Ann Clin Biochem 2008, 45(4):345-348.

19. Milani RV, Lavie CJ: Homocysteine: the Rubik’s cube of cardiovascular risk factors. Mayo Clin Proc 2008, 83(11):1200-1202.

20. Hazanova A, Folsom AR, Ibrahim H, Javier Nieto F, Rosamond WD, Shahar E: Serum uric acid and risk of ischemic stroke: the ARIC Study. Atherosclerosis 2006, 187(2):401-407.

21. Leyva F, Anker S, Swan JW, Godlass IF, Wingrove CS, Chua TP, Stevenson JC, Coats AJ: Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J 1997, 18(5):858-865.

22. Malinow MR, Levenson J, Giral P, Nieto FJ, Razavian M, Segond P, Simon A: Role of blood pressure, uric acid, and hemorheological parameters on plasma homocysteine concentration. Atherosclerosis 1995, 114(2):175-183.

23. Kang DH, Park SK, Lee IK, Johnson RJ: Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. Atherosclerosis 2005, 201(1):117-122.

24. Sarnak MJ, Levey AS, Levin J, Kusek JW, Coresh J, Greene T, Howard G, Klag MJ: Kidney disease as a risk factor for development of cardiovascular disease: a 15-year follow-up of the Third National Health and Nutrition Examination Survey, 1988-1991. Ann Intern Med 1997, 126(1):354-360.

25. Kitas G, Zintzas E: Genetic variation associated with ischemic heart failure: a HuGE review and meta-analysis. Am J Epidemiol 2007, 166(6):619-633.

26. Zintzas G, Zoubidakis E, Humphries SE: The use of meta-analysis risk estimates for candidate genes in combination to predict coronary heart disease risk. Annals of human genetics 2007, 71(PT 5):611-619.

27. Zintzas E, Zoubidakis E: A field synopsis and meta-analysis of genetic association studies in peripheral arterial disease: the CUMAGAS-PAD database. Am J Epidemiol 2009, 170(1):1-11.

28. Maou K, Katsa S, Tsavanis T, Yv K, Roubi M, Dparha T, Tuck ML, Beta-2 and beta-3 adrenergic receptor polymorphisms are related to the onset of weight gain and blood pressure elevation over 5 years. Circulation 2005, 111(25):3429-3434.

29. Balistreri CR, Colonza-Romano G, Lio D, Candore G, Caruso C: TLBR polymorphisms and ageing: implications for the pathophysiology of age-related diseases. J Clin Immunol 2009, 29(4):406-415.

30. Lavoie DA, Harbord RM, Timpong NJ, Lowe GD, Rumley A, Gaunt TR, Baker I, Yamell JW, Kivimaki M, Kumari M, Norman PE, Jamrozik K, Hankey GJ, Almeida OP, Flicker L, Warrington N, Marmot MG, Ben-Shlomo Y, Palmer LJ, Day IN, Ebrahim S, Smith GD: The association of C-reactive protein and CRP genotype with coronary heart disease: findings from five studies with 4,610 cases amongst 18,637 participants. PLoS One 2008, 3(8):e3011.

31. Haider DG, Leuchten N, Schaller G, Gouya G, Kolodjaschna J, Schmetterer L, Kaprots S, Wolzt M: C-reactive protein is expressed and secreted by peripheral blood mononuclear cells. Clin Exp Immunol 2006, 146(3):539-543.

32. Doodenhof GV, Panagiotakos DB, Pittas C, Chesnouhla C, Skoumas J, Choumenianou D, Stapeladies C: A association between the methylenetetrahydrofolate reductase (MTHFR) 677 TT mutation and inflammation markers related to cardiovascular disease. Int J Cardiol 2005, 100(3):409-414.

33. Ridker PM, Pare G, Parker A, Zee RY, Danis JK, Burin JE, Kwiatkowski D, Cook NR, Miletich JP, Charnson DI: Loci related to metabolic-syndrome pathways including LEP, HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women’s Genome Health Study, Am J Hum Genet 2008, 82(5):1185-1192.

34. Reiner AP, Barber MJ, Guan Y, Ridker PM, Lange LA, Chalmers DI, Wall сторон JW, Gropper GM, Jenney NS, Rieder MJ, Dutta JP, Smith JD, Novembre J, Tracy RP, Rotter JB, Stephens M, Nickerson DA, Kraus RM: Polymorphisms of the HNF1A gene encoding hepatocyte nuclear factor-1 alpha are associated with C-reactive protein. Am J Hum Genet 2008, 82(5):1193-1201.

35. Crawford DC, Sanders CL, Qin X, Smith JD, Sheikh C, Wong M, Witrak L, Rieder MJ, Nickerson DA: Genetic variation is associated with C-reactive protein levels in the Third National Health and Nutrition Examination Survey. Circulation 2006, 114(23):2458-2465.

36. McQuillan GM, Porter KS, Agelli M, Kington R: Consent for genetic research in a general population: the NHANES experience. Genet Med 2003, 5(1):35-42.

37. National Center for Health Statistics: Laboratory procedures used for NHANES III. Hyattsville, MD 1994Available from: http://www.cdc.gov/nchs/data/nhanes/nhanes.html/cdrom/nchs/manuals/labman.pdf.

38. Gonzalez JR, Carrasco JL, Dudbridge F, Amengual L, Estivil X, Moreno V: Maximizing association statistics over genetic models. Genet Epidemiol 2008, 32(3):246-254.

39. Andreotti F, Porta I, Crea F, Maseri A: Inflammatory gene polymorphisms and ischaemic heart disease: review of population association studies. Heart 2002, 87(2):107-112.

40. Barbaux S, Tegrouet DA, Nicaud V, Poirier O, Perret C, Godefroy T, Francombe C, Combadiere C, Arveiller D, Luc G, Ruidavets JB, Evans AE, Kee F, Morrison C, Tzoulaki I, Erdmann J, Braund P, Engert JC, Bennett D, Coin L, Ashby D, Tzoulaki I.
Brown IJ, Mt-Isa S, McCarthy MI, Petlonen L, Freimer NB, Farrall M, Ruokonen A, Hamsten A, Lim N, Froguel P, Waterworth DM, Vollenweider P, Waeber G, Jarvelin MR, Mooser V, Scott J, Hall AS, Schunkert H, Anand SS, Collins R, Samani NJ, Watkins H, Kooner JS. Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 2009, 302(1):37-48.

Hamsten A, Iselius L, de Faire U, Blomback M. Genetic and cultural inheritance of plasma fibrinogen concentration. Lancet 1987, 2(8566):988-991.

Folsom AR, Pankow JS, Williams RR, Evans GW, Province MA, Eckfeldt JH. Fibrinogen, plasminogen activator inhibitor-1, and carotid intima-media wall thickness in the NHLBI Family Heart Study. Thromb Haemost 1998, 79(2):400-404.

Reinhart WH. Fibrinogen—marker or mediator of vascular disease?. Vasc Med 2003, 8(3):211-216.

Schulz S, Schädgenrungrung U, Suss T, Muller-Werdan K, Glaser C. Relation between the tumor necrosis factor-alpha (TNF-alpha) gene and protein expression, and clinical, biochemical, and genetic markers: age, body mass index and uric acid are independent predictors for an elevated TNF-alpha plasma level in a complex risk model. Eur Cytokine Netw 2004, 15(2):105-111.

Vitart V, Rudan I, Hayward C, Gray NK, Floyd J, Palmer CN, Knott SA, Kolarcik J, Zgaga L, Oudshoorn NC, Grischkowsky D, Smolderen KM, Takahashi Y, Souto JC, Fontcuberta J, Peden J, Andersen M, Skaric-Juric T, Wild SH, Richardson WA, Hohenstein P, Kimmer CH, Tenesa A. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excetration and gout. Nat Genet 2008, 40(4):437-442.

Bautista LE. Inflammation, endothelial dysfunction, and the risk of high blood pressure: epidemiologic and biological evidence. J Hum Hypertens 2003, 17(4):223-230.

Lazerini FE, Capecchi PL, Selvi E, Lorenzini S, Bisogno S, Galeazzi M, Laghi Pasini F. Hyperhomocysteinemia, inflammation and autoimmunity. Autoimmun Rev 2007, 6(7):523-529.

Bis JC, Glazer NL, Piaty BM. Genome-wide association studies of cardiovascular risk factors: design, conduct and interpretation. J Thromb Haemost 2009, 7(Suppl 1):308-311.